Effect of obesity on serum amiodarone concentration in Japanese patients: Population pharmacokinetic investigation by multiple trough screen analysis

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 3, 2009, Pages 329-336

  Fukuchi, H ^a   Nakashima, M ^a   Araki, R ^a   Komiya, N ^a   Hayano, M ^a   Yano, K ^a   Sasaki, H ^a   Yukawa, E ^b  

^a NAGASAKI UNIVERSITY   (Japan)

^b DAIICHI UNIVERSITY OF PHARMACY   (Japan)

Author keywords

Amiodarone; Clearance; Japanese patients; Non linear mixed effects modelling; Obesity; Population pharmacokinetics

Indexed keywords

AMIODARONE; ANCARON; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPANESE; MALE; MODEL; NONLINEAR MIXED EFFECT MODELLING; OBESITY; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; BODY MASS INDEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NONLINEAR DYNAMICS; OBESITY; RETROSPECTIVE STUDIES; TISSUE DISTRIBUTION;

EID: 65549166443     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00987.x     Document Type: Article

References (28)

1. Gill J, Heel RC, Fitton A (1992) Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs, 43, 69 110.
2. Greene HL (1993) The CASCADE study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest. CASCADE investigators. American Journal of Cardiology, 72, 70F 74F. (Pubitemid 23360758)
3. Somani P (1989) Basic and clinical pharmacology of amiodarone: relationship of antiarrhythmic effects, dose and drug concentrations to intracellular inclusion bodies. Journal of Clinical Pharmacology, 29, 405 412. (Pubitemid 19143597)
4. Roden DM (1993) Pharmacokinetics of amiodarone: implications for drug therapy. American Journal of Cardiology, 72, 45F 50F. (Pubitemid 23360754)
5. Adams PC, Holt DW, Storey GC, Morley AR, Callaghan J, Campbell RW (1985) Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation, 72, 1064 1075. (Pubitemid 16205408)
6. Andreasen F, Agerbaek H, Bjerregaard P, Gotzsche H (1981) Pharmacokinetics of amiodarone after intravenous and oral administration. European Journal of Clinical Pharmacology, 19, 293 299. (Pubitemid 11142988)
7. Anastasiou-Nana M, Levis GM, Moulopoulos S (1982) Pharmacokinetics of amiodarone after intravenous and oral administration. International Journal of Clinical Pharmacology Therapy and Toxicology, 20, 524 529.
8. Riva E, Gerna M, Latini R, Giani P, Volpi A, Massioni A (1982) Pharmacokinetics of amiodarone in man. Journal of Cardiovascular Pharmacology, 4, 264 269.
9. Holt DW, Tucker GT, Jackson PR, Storey GCA (1983) Amiodarone pharmacokinetics. American Heart Journal, 106, 840 847.
10. Staubli M, Bircher J, Galeazzi RL, Remund H, Studer H (1983) Serum concentrations of amiodarone during long term therapy: relation to dose, efficacy and toxicity. European Journal of Clinical Pharmacology, 24, 485 494.
11. Staubli M, Troendle A, Schmid B, Balmer P, Kohler B, Studer H, Bircher J (1985) Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. European Journal of Clinical Pharmacology, 29, 417 423. (Pubitemid 16192597)
12. Pollak PT, Bouillon T, Shafer SL (2000) Population pharmacokinetics of long-term oral amiodarone therapy. Clinical Pharmacology and Therapeutics, 67, 642 652. (Pubitemid 30416080)
13. Dunn TE, Ludwiq EA, Slaughter RL, Camara DS (1991) Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clinical Pharmacology and Therapeutics, 49, 536 549.
14. Cheymol G (1993) Clinical pharmacokinetics of drugs in obesity: an update. Clinical Pharmacokinetics, 25, 103 114. (Pubitemid 23232390)
15. Cheymol G. (2000) Effects of obesity on pharmacokinetics: implications for drug therapy. Clinical Pharmacokinetics, 39, 215 231.
16. Watson AM, Poloyac SM, Howard G, Blouin RA (1999) Effect of leptin on cytochrome P450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metabolism and Disposition, 27, 695 700. (Pubitemid 29252444)
17. Leclercq IA, Field J, Enriquez A, Farrell GC, Robertson GR (2000) Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. Biochemical and Biophysical Research Communications, 268, 337 344. (Pubitemid 30119623)
18. Cheng PY, Morgan ET (2001) Hepatic cytochrome P450 regulation in disease states. Current Drug Metabolism, 2, 165 183. (Pubitemid 32544553)
19. Kotlyar M, Carson SW (1999) Effects of obesity on the cytocrome P450 enzyme system. International Journal of Clinical Pharmacology and Therapeutics, 37, 8 19. (Pubitemid 29043392)
20. Beal SL, Sheiner LB eds 1992) NONMEM users guides. University of California at San Francisco, San Francisco : NONMEM Project Group.
21. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics, 9, 503 512.
22. Latini R, Bizzi A, Cini M, Veneroni E, Marchi S, Riva E (1987) Amiodarone and desethylamiodarone tissue uptake in rats chronically treated with amiodarone is non-linear with the dose. Journal of Pharmacy and Pharmacology, 39, 426 431. (Pubitemid 17114398)
23. Sheiner LB, Benet LZ (1985) Premarketing observational studies of population pharmacokinetics of new drug. Clinical Pharmacology and Therapeutics, 38, 481 487. (Pubitemid 16193885)
24. Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T (1997) Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. Journal of Clinical Pharmacology, 37, 92 100. (Pubitemid 27131539)
25. Yukawa E, Akiyama K, Suematsu F, Yukawa M, Minemoto M (2007) Population pharmacokinetic investigation of digoxin in Japanese neonates. Journal of Clinical Pharmacy and Therapeutics, 32, 381 386. (Pubitemid 47063162)
26. Latini R, Tognoni G, Kates RE (1984) Clinical pharmacokinetics of amiodarone. Clinical Pharmacokinetics, 9, 136 156. (Pubitemid 14164705)
27. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T (2000) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metabolism and Disposition, 28, 1303 1310.
28. Kashima A, Funahashi M, Fukumoto K, Komamura K, Kamakura S, Kitakaze M, Ueno K (2005) Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population. Biological and Pharmaceutical Bulletin, 28, 1934 1938. (Pubitemid 41437084)